Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

RHHBY : 39.1100 (+1.09%)
SGEN : 135.46 (+0.14%)
APTO : 0.5444 (+0.35%)
LVTX : 4.99 (+5.27%)
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global...

ZLAB : 38.73 (+3.47%)
SGEN : 135.46 (+0.14%)
GMAB : 31.61 (+0.29%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

LVTX : 4.99 (+5.27%)
SGEN : 135.46 (+0.14%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 135.46 (+0.14%)
LVTX : 4.99 (+5.27%)
Worried About the Stock Market? Take Warren Buffett's Advice and Do This

The billionaire investor is a big believer in betting on America.

ORCL : 62.17 (-2.02%)
SGEN : 135.46 (+0.14%)
TMUS : 131.78 (-0.41%)
KO : 56.67 (-2.07%)
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.

RHHBY : 39.1100 (+1.09%)
SGEN : 135.46 (+0.14%)
APTO : 0.5444 (+0.35%)
ORIC : 3.08 (-2.22%)
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) seeking accelerated approval for...

SGEN : 135.46 (+0.14%)
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Sector ETF report for FBT

FBT : 129.35 (+0.58%)
UTHR : 204.04 (+0.36%)
IBB : 114.39 (+0.86%)
SGEN : 135.46 (+0.14%)
GRFS : 6.60 (-4.49%)
XBI : 76.46 (+1.87%)
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen Inc. (Nasdaq:SGEN), Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced...

SGEN : 135.46 (+0.14%)
MRK : 86.21 (+0.03%)
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

FBT : 129.35 (+0.58%)
UTHR : 204.04 (+0.36%)
IBB : 114.39 (+0.86%)
SGEN : 135.46 (+0.14%)
GRFS : 6.60 (-4.49%)
XBI : 76.46 (+1.87%)

Barchart Exclusives

Here’s a Real Estate Play That Nobody Follows
While U-Haul is Amerco’s primary revenue generator, the company’s real estate assets make it a possible diamond in the rough. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar